NYSE: GBX 1Q26 Earnings Slides & Supplemental Information InvestorRelations@gbrx.com www.gbrx.com Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements, including statements that are not purely statements of historical fact. The Greenbrier Companies, Inc. (the "Company," "we," "us" or "our") uses words, and variations of words, such as "backlog," "believe," "capacity," "commit," "continue," "drive," "estimate," "expect," "focus," "future," "gr ...

Earnings Call: Q1 - FY26 January 8, 2026 $0.03 Diluted EPS $18.4M Revenue 19% Adj. EBITDA Margin -3% Revenue Decline Current period Prior Year Comparison (1Q25) $0.13 Adj. Diluted EPS $18.9M Revenue $0.01 Diluted EPS 24% Adj. EBITDA Margin +31% $0.17 Revenue Growth Adj. Diluted EPS Trailing Twelve Months (TTM) Highlights ($3.20) Diluted EPS (1) $78.7M Revenue 27% Adj. EBITDA Margin +6% Revenue Growth Current period Prior Year Comparison (1Q25) $0.98 Adj. Diluted EPS $74.4M Revenue $0.40 Diluted EPS 29% Adj. ...

Phase 2 COACH Trial Topline Week 52 Data January 8, 2026 Treatment with TransCon CNP and TransCon hGH combination therapy is investigational. For investor communication only. Not for use in product promotion. Not for further distribution. Cautionary Note on Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, such as statements regarding TransCon hGH's ability to complement TransCon CNP's ho ...

CORAL-1 Clinical Data Update - Krystal Biotech's KB407 is a gene therapy for cystic fibrosis (CF) and has the potential to become a leadership opportunity in the treatment of CF[9] - The company plans to initiate the CORAL-3 study in the first half of 2026 to evaluate the safety and efficacy of repeat KB407 administration, which could support registration of KB407[4, 93] - The company estimates a $2 billion+ market opportunity in modulator-ineligible or refractory CF patients[12] KB407 Phase 1 CORAL-1 Highest Dose Cohort Results - In patient 03-01 with CFTR genotype 2184delA/W1282X, 42.1% of conducting airway cells expressed CFTR[55] - In patient 03-02 with CFTR genotype R553X/M1V, 29.4% of conducting airway cells expressed CFTR[68] - In patient 03-03 with CFTR genotype C1210-12T/1408A>G, 36.5% of conducting airway cells were viral marker positive[76] - In patient 03-04 with CFTR genotype R334W/R1162X, 33.8% of conducting airway cells were viral marker positive[79] - In patient 03-05 with CFTR genotype F508del/F508del, 36.8% of conducting airway cells were viral marker positive[81] - In patient 03-06 with CFTR genotype F508del/F508del, 31.4% of conducting airway cells were viral marker positive[83]

RESPONSIBLE CARE® OUR COMMITMENT TO SUSTAINABILITY Refer to the Appendix for additional notices of caution regarding forward looking information. 2 TSX: CHE.UN 2026 Guidance 2026 Guidance: 2026 GUIDANCE Chemtrade Logistics Income Fund (TSX: CHE.UN) January 8, 2026 CAUTION REGARDING FORWARD- LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking statements within the meaning of certain securities laws, including the Securities Act (Ontario). Forward-looking statements ...

2026 PriceSmart, Inc. Overview Presentation Issued: January 2026 NASDAQ : PSMT 1 ForwardLookingStatements This presentation may contain forward-looking statements concerning PriceSmart, Inc.'s ("PriceSmart", the "Company" or "we") anticipated future revenues and earnings, adequacy of future cash flows, omni-channel initiatives, proposed warehouse club openings, the Company's performance relative to competitors and related matters. These forward-looking statements include, but are not limited to, statements ...

Financial Performance & Growth - Since Q1 2023, NewtekOne's book value/share has increased by 45% from $8.06 to $11.72[14] - Tangible common book value (TBV)/share has increased by 62% from $6.92 to $11.22 since Q1 2023[14] - NewtekOne has distributed $2.05 of common dividends/share over the eleven quarters since transitioning to a financial holding company[14] - The company's operating efficiency ratio has improved from over 70% in 2023 to 56.3% as of September 30, 2025[44] - Hypothetical $300 million loan pool generates $22.7 million of annual net interest income[84] Lending & Securitization - Approximately $850 million of originations across 180 loans in C&I loans held for sale since 2018[75] - The ALP securitization completed in April 2025 generates 570 bps of spread income after FV mark on securitization not including 100 bps of servicing income[75] - The advance rate for the 2026-1 securitization is 86%, with an ALP Loan Pool of $340 million[76] Newtek Advantage Platform - Newtek Bank has grown to $1.5 billion in assets (7x over three years) since acquisition[44] - The platform generates approximately 600 new referrals per day as a client acquisition tool[44] - In 2025, NewtekOne originated over $1.4 billion in loans[45]

Financial Performance & Outlook - Q1 Net Earnings reached $1773 million[15], while Adjusted Earnings were $2062 million[15] - Q1 Core EBITDA stood at $3169 million[15], with a Core EBITDA Margin of 149%[15] - The company aims to exit FY 2026 with an annualized run-rate EBITDA benefit of $150 million from TAG initiatives[14, 21] - Precast business is expected to contribute approximately $165 million to $175 million to Construction Solutions Group Adjusted EBITDA in fiscal 2026[34] Strategic Initiatives - The company launched new Transform, Advance, Grow ("TAG") initiatives with commercial opportunities in focus[14, 19] - The company rebranded Emerging Businesses Group to Construction Solutions Group to better reflect business composition and strategic role of segment[14, 28] - The company completed acquisitions of Concrete Pipe & Precast ("CP&P") and Foley Products Company ("Foley")[2, 34] Market Dynamics - Construction Solutions Group net sales were up 170% year-over-year, while adjusted EBITDA increased by 747%[52, 65] - Europe Steel Group shipments increased by 157% on a year-over-year basis[52, 72] - The company anticipates reducing net debt to adjusted EBITDA to below 2x within 18 months[14, 46]

Financial Performance - Revenue decreased by $10.5 million, a 6 percent decrease compared to the prior year[10] - Operating income decreased by $1.3 million, a 6 percent decrease compared to the prior year[10] - Diluted earnings per share decreased by $0.03 per share, a 2 percent decrease compared to the prior year[10] - Irrigation revenue decreased by $13.7 million[10] - Infrastructure revenue increased by $3.2 million[10] Irrigation Segment - Irrigation North America revenue decreased 4 percent to $74.3 million[15] - Irrigation international revenue decreased 15 percent to $59.1 million, but included a favorable foreign currency translation effect of $1.5 million[17] Infrastructure Segment - Infrastructure revenue increased 17 percent to $22.4 million[25] - Infrastructure operating income increased 9 percent to $4.5 million[25] Market Factors & Highlights - USDA estimated 2025 U S net farm income to be $179.8 billion, a 41 percent increase from 2024 U S net farm income of $127.8 billion[12] - The company completed share repurchases of $30 million during the quarter[7] - The company secured an $80 million irrigation and technology project in the MENA region subsequent to quarter-end[7]

Financial Performance - The company updated its FY26 reported EPS outlook to $972-$1002 and affirmed a comparable EPS outlook of $1130-$1160[16] - The company affirmed FY26 targets for operating cash flow of $25 billion to $26 billion and free cash flow of $13 billion to $14 billion[16] - Enterprise Q3 FY26 reported net sales were $2223 billion, a 10% decrease year-over-year, while organic net sales also reached $2223 billion, reflecting a 2% decrease[21, 24] - Enterprise Q3 FY26 reported operating income was $692 million, a 13% decrease year-over-year, but comparable operating income was $739 million, remaining flat[21, 28] Segment Results - The Beer Business experienced a 1% decrease in net sales, reaching $20 billion in Q3 FY26[21] - The Wine and Spirits Business reported a 51% decrease in net sales to $213 million, with organic net sales down 7%[21] - The Wine and Spirits Business operating margin contracted significantly from 221% to 158%[17] Capital Allocation - The company maintained a net leverage ratio at the target of approximately 30X[17, 19] - The company executed $220 million in share repurchases in Q3, bringing the fiscal year-to-date total to $824 million[17, 19] - Capital expenditures in Q3 were $246 million, with a fiscal year-to-date total of $656 million, primarily focused on Beer brewing capacity additions[17, 19] Strategic Initiatives - The company achieved a net benefit through efficiency and cost optimization initiatives of over $40 million in Q3 FY26 and over $145 million fiscal year-to-date[20]